LUNG (Pulmonx Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LUNG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Srikanth Radhakrishnan | Chief Science & Techn. Officer | Sell | — | — |
| 2026-09-03 | Geoffrey Beran Rose | Chief Commercial Officer | Sell | — | — |
| 2026-09-03 | Glendon E. French III | President and CEO | Sell | — | — |
| 2026-09-03 | David Aaron Lehman | General Counsel | Sell | — | — |
| 2026-06-09 | Richard Ferrari | Director | A | — | — |
| 2026-06-09 | Dana G Mead Jr. | Director | A | — | — |
| 2026-06-09 | Daniel P Florin | Director | A | — | — |
| 2026-06-09 | Tiffany Sullivan | Director | A | — | — |
| 2026-06-09 | Georgia Melenikiotou | Director | A | — | — |
| 2026-06-09 | Thomas William Burns | Director | A | — | — |
| 2026-06-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2026-06-03 | Glendon E. French III | President and CEO | Sell | — | — |
| 2026-06-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | — | — |
| 2026-06-03 | Srikanth Radhakrishnan | Chief Science &Techn. Officer | Sell | — | — |
| 2026-03-04 | David Aaron Lehman | GENERAL COUNSEL | MIXED | — | — |
| 2026-03-04 | Srikanth Radhakrishnan | Chief Science &Techn. Officer | MIXED | — | — |
| 2026-03-04 | Glendon E. French III | President and CEO | Sell | — | — |
| 2026-03-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-12-09 | Daniel P Florin | Director | Sell | — | — |
| 2025-12-03 | Derrick Sung | COO and CFO | A | — | — |
| 2025-12-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | — | — |
| 2025-12-03 | Glendon E. French III | President and CEO | MIXED | — | — |
| 2025-12-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2025-09-03 | Mehul Joshi | Chief Financial Officer & PAO | Sell | — | — |
| 2025-09-03 | David Aaron Lehman | GENERAL COUNSEL | Sell | — | — |
| 2025-09-03 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2025-09-03 | Steven S. Williamson | PRESIDENT AND CEO | Sell | — | — |
| 2025-06-13 | Richard Ferrari | Director | Sell | — | — |
| 2025-06-05 | Daniel P Florin | Director | Buy | — | — |
| 2025-06-04 | Daniel P Florin | Director | A | — | — |
| 2025-06-04 | Thomas William Burns | Director | A | — | — |
| 2025-06-04 | David Aaron Lehman | GENERAL COUNSEL | Sell | — | — |
| 2025-06-04 | Tiffany Sullivan | Director | A | — | — |
| 2025-06-04 | Georgia Melenikiotou | Director | A | — | — |
| 2025-06-04 | Steven S. Williamson | PRESIDENT AND CEO | Sell | — | — |
| 2025-06-04 | Richard Ferrari | Director | A | — | — |
| 2025-06-04 | Mehul Joshi | Chief Financial Officer & PAO | Sell | — | — |
| 2025-06-04 | Dana G Mead Jr. | Director | A | — | — |
| 2025-06-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2025-06-04 | Glendon E. French III | Director | A | — | — |
| 2025-03-21 | Glendon E. French III | Director | Sell | — | — |
| 2025-03-05 | Mehul Joshi | Chief Financial Officer & PAO | MIXED | — | — |
| 2025-03-05 | Steven S. Williamson | PRESIDENT AND CEO | MIXED | — | — |
| 2025-03-05 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | MIXED | — | — |
| 2025-03-05 | David Aaron Lehman | GENERAL COUNSEL | MIXED | — | — |
| 2025-02-24 | Glendon E. French III | Director | Sell | — | — |
| 2025-01-21 | Glendon E. French III | Director | Sell | — | — |
| 2024-12-04 | Geoffrey Beran Rose | CHIEF COMMERCIAL OFFICER | Sell | — | — |
| 2024-12-04 | David Aaron Lehman | GENERAL COUNSEL | Sell | — | — |
| 2024-11-26 | Glendon E. French III | Director | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 2,093,918 | — |
| — | 10%+ Owner | 1,488,106 | — |
| — | Director | 1,359,345 | — |
| — | COO and CFO | 1,335,319 | — |
| — | Director | 1,116,724 | — |
| — | Chief Commercial Officer | 451,578 | — |
| — | General Counsel | 372,354 | — |
| — | PRESIDENT AND CEO | 363,497 | — |
| — | Chief Science & Techn. Officer | 316,994 | — |
| — | Chief Financial Officer & PAO | 212,154 | — |
| — | Director | 149,699 | — |
| — | Director | 143,790 | — |
| — | Director | 139,714 | — |
| — | Director | 115,199 | — |
| — | Director | 113,399 | — |
| — | INTERIM CFO | 76,210 | — |
| — | Director | 24,530 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LUNG quote page; the site-wide leaderboard is on the insider transactions hub.